Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14605637 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL5461273 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL6871388 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL2178522 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL9169159 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL13314011 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14605828 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL9733234 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14117906 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 | |
| SCHEMBL14117911 | 1.00 | TSHR (0.56) | TSHRFKBP1AALDH1A1BACE1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521566-B2 | Process for preparation of perindopril and salts thereof | LES LABORATOIRES SERVIER (FR) | 2009-04-21 | — | — | US | disclosed |
| US-7456296-B2 | Method for preparation of crystalline perindopril erbumine | LUPIN LTD (IN) | 2008-11-25 | — | — | US | disclosed |
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | LUPIN LTD. (IN) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149604-A1 | Reacting perindopril in a solvent selected from N,N-dimethylformamide, dimethoxymethane, 2,2-dimethoxypropane and 1,2-dimethoxyethane with tert-butylamine, crystallization; stereospecific | REN, AGTR2, AGTR1 | TSHR 2109/4885FKBP1A 417/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.